Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$12.36 USD
0.00 (0.00%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $12.36 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
NRIX 12.36 0.00(0.00%)
Will NRIX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NRIX
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?
Other News for NRIX
First Week of NRIX June 21st Options Trading
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Nurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectations